Management of Multiple Sclerosis in the Breastfeeding Mother.

IF 2.2 Q3 CLINICAL NEUROLOGY
Multiple Sclerosis International Pub Date : 2016-01-01 Epub Date: 2016-02-04 DOI:10.1155/2016/6527458
Saneea Almas, Jesse Vance, Teresa Baker, Thomas Hale
{"title":"Management of Multiple Sclerosis in the Breastfeeding Mother.","authors":"Saneea Almas, Jesse Vance, Teresa Baker, Thomas Hale","doi":"10.1155/2016/6527458","DOIUrl":null,"url":null,"abstract":"<p><p>Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers. </p>","PeriodicalId":46096,"journal":{"name":"Multiple Sclerosis International","volume":null,"pages":null},"PeriodicalIF":2.2000,"publicationDate":"2016-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757692/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Multiple Sclerosis International","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2016/6527458","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2016/2/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers.

母乳喂养母亲的多发性硬化管理。
多发性硬化症(MS)是一种以大脑和脊髓炎症为特征的自身免疫性神经系统疾病。复发性多发性硬化症的特点是急性发作,随后缓解。治疗的目的是阻止这些发作;治疗可能持续数月至数年。由于多发性硬化症对女性的影响尤为严重,而且通常在育龄期发病,因此临床医生会对怀孕或哺乳期的多发性硬化症患者进行治疗。本综述旨在深入分析用于哺乳期多发性硬化症女性患者的药物的安全性。本文介绍了用于治疗多发性硬化症的几种药物及其在哺乳期的安全性研究,包括免疫调节剂、免疫抑制剂、单克隆抗体、皮质类固醇和用于对症治疗的药物。通常情况下,一些药物是大极性分子,通常不会以临床相关的量进入乳汁。因此,给哺乳期母亲服用β干扰素可能对婴儿是安全的。然而,其他副作用特别危险的药物可能不推荐使用。虽然有治疗方案可供选择,也有一些临床研究数据,但仍有必要对母乳喂养母亲使用的药物进行调查和持续审查。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Multiple Sclerosis International
Multiple Sclerosis International CLINICAL NEUROLOGY-
自引率
0.00%
发文量
6
审稿时长
15 weeks
期刊介绍: Multiple Sclerosis International is a peer-reviewed, Open Access journal that publishes original research articles, review articles, and clinical studies related to all aspects of multiple sclerosis, including clinical neurology, neuroimaging, neuropathology, therapeutics, genetics, neuroimmunology, biomarkers, psychology and neurorehabilitation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信